Telix Pharmaceuticals Limited - Laporan Laba Rugi (TTM)

Telix Pharmaceuticals Limited
US ˙ OTCPK ˙ AU000000TLX2

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Telix Pharmaceuticals Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 4 5 6 7 7 8 18 29 94 160 249 357 430 503 576 428 714 783 575 664
Change (%) 22.83 12.50 11.11 8.29 7.65 139.13 58.18 228.59 69.57 55.75 43.13 20.41 16.95 14.67 -25.80 67.09 9.62 -26.65 15.62
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 2 2 2 2 2 3 7 12 39 65 98 141 169 198 209 166 275 299 250 306
Change (%) -14.87 -1.04 -1.05 14.28 12.49 190.21 65.54 216.20 68.37 50.92 43.05 20.37 16.93 5.71 -20.93 65.99 8.93 -16.55 22.51
% of Revenue 56.02 38.83 34.15 30.42 32.10 33.54 40.71 42.60 41.00 40.71 39.44 39.42 39.41 39.40 36.32 38.71 38.45 38.21 43.47 46.06
Gross Operating Profit 2 3 4 5 5 5 11 16 56 95 151 216 260 305 367 262 440 484 325 358
Change (%) 70.85 21.09 17.42 5.67 5.36 113.35 53.13 237.79 70.40 59.07 43.17 20.43 16.96 20.50 -28.58 67.79 10.06 -32.89 10.32
% of Revenue 43.98 61.17 65.85 69.58 67.90 66.46 59.29 57.40 59.00 59.29 60.56 60.58 60.59 60.60 63.68 61.29 61.55 61.79 56.53 53.94
SG&A 22 24 28 32 39 47 63 79 83 87 89 92 108 124 153 110 186 207 149 169
Change (%) 13.77 14.89 12.96 23.96 19.33 34.31 25.54 4.97 4.73 2.39 3.38 17.41 14.83 23.12 -27.88 68.65 11.29 -28.13 13.32
% of Revenue 506.88 469.50 479.50 487.51 558.05 618.56 347.42 275.74 88.08 54.40 35.77 25.83 25.19 24.73 26.55 25.81 26.05 26.45 25.91 25.40
R&D 23 23 26 28 31 34 40 45 63 81 91 105 117 129 145 109 179 195 138 154
Change (%) 2.57 10.97 9.89 10.63 9.61 16.37 14.06 39.40 28.26 11.75 15.87 11.27 10.13 13.05 -25.20 64.99 8.54 -28.98 11.23
% of Revenue 530.30 442.84 436.82 432.01 441.36 449.38 218.68 157.69 66.89 50.60 36.30 29.39 27.16 25.58 25.22 25.42 25.10 24.85 24.06 23.15
OpEx 51 54 61 67 78 89 115 142 188 234 297 337 394 451 490 389 640 701 542 636
Change (%) 6.88 11.50 10.31 16.31 14.02 29.99 23.07 32.39 24.47 26.95 13.19 16.96 14.50 8.79 -20.62 64.40 9.61 -22.75 17.41
% of Revenue 1,200.77 1,044.81 1,035.53 1,028.10 1,104.27 1,169.60 635.77 494.64 199.30 146.29 119.23 94.30 91.59 89.67 85.08 91.02 89.55 89.54 94.31 95.77
Operating Income -47 -49 -55 -60 -71 -81 -97 -113 -94 -74 -48 20 36 52 86 38 75 82 33 28
Change (%) 5.43 11.39 10.23 17.17 14.66 19.78 16.52 -17.32 -20.95 -35.28 -142.44 77.45 43.65 65.72 -55.37 94.44 9.74 -60.05 -14.11
% of Revenue -1,100.77 -944.81 -935.53 -928.10 -1,004.27 -1,069.60 -535.77 -394.64 -99.30 -46.29 -19.23 5.70 8.41 10.33 14.92 8.98 10.45 10.46 5.69 4.23
Interest Expense -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -3 -1 -1 -1 -2 -1 -4 -7 -5 -11
Change (%) 2.96 -5.76 -6.11 -1.78 -1.81 10.74 9.70 31.57 23.99 867.03 -81.75 18.77 15.81 112.24 -64.21 583.72 77.95 -27.03 101.16
% of Revenue -4.37 -3.66 -3.07 -2.59 -2.35 -2.15 -0.99 -0.69 -0.28 -0.20 -1.25 -0.16 -0.16 -0.16 -0.29 -0.14 -0.57 -0.93 -0.92 -1.60
Net Income -40 -45 -52 -59 -70 -81 -100 -119 -111 -104 -77 -48 -21 5 32 33 50 50 19 11
Change (%) 11.26 15.83 13.67 18.11 15.34 23.83 19.25 -6.23 -6.64 -25.90 -38.40 -55.48 -124.64 507.89 2.98 51.90 0.74 -62.38 -42.25
% of Revenue -950.59 -861.06 -886.58 -907.00 -989.30 -1,059.90 -548.86 -413.76 -118.08 -65.01 -30.93 -13.31 -4.92 1.04 5.50 7.63 6.94 6.37 3.27 1.63

Source: Capital IQ

Other Listings
MX:TLX1 N
DE:T3X
AU:TLX A$ 13.80
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista